{"id":415188,"date":"2021-01-14T11:48:32","date_gmt":"2021-01-14T16:48:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=415188"},"modified":"2021-01-14T11:48:32","modified_gmt":"2021-01-14T16:48:32","slug":"poxel-regains-imeglimin-rights-from-metavant","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/","title":{"rendered":"Poxel Regains Imeglimin Rights From Metavant"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\" style=\"font-weight:normal\"><b>Poxel Regains Imeglimin Rights From Metavant<\/b><\/p>\n<p style=\"font-weight:normal\">LYON, France&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxel.com%2F&amp;esheet=52362077&amp;newsitemid=20210114005819&amp;lan=en-US&amp;anchor=POXEL+SA&amp;index=1&amp;md5=cf3971008ce4668a084420b424615ca4\">POXEL SA<\/a> (Euronext: POXEL &#8211; FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that, as part of the previously communicated decision by Metavant not to advance Imeglimin into a Phase 3 program for strategic reasons, its partnership agreement with Metavant will be terminated, effective January 31, 2021. Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program. Metavant is not entitled to any payment from Poxel as part of the return of the program.\n<\/p>\n<p>\n\u201cWe remain convinced of Imeglimin\u2019s value as an innovative new drug for type 2 diabetes. A New Drug Application in Japan (J-NDA) is currently advancing through regulatory review with our partner Sumitomo Dainippon Pharma, and a target product launch is anticipated in fiscal year 2021<sup>1<\/sup>. Moving forward, we are considering various options to advance Imeglimin in the US, Europe and other countries not covered by our agreement with Sumitomo Dainippon Pharma and we are looking forward to updating the market on our progress. In the meantime, we continue to remain focused on the further development of our metabolic disease pipeline,\u201d said Thomas Kuhn, CEO of Poxel.\n<\/p>\n<p><b>About Poxel SA<\/b><\/p>\n<p>\nPoxel is a <b>dynamic biopharmaceutical company<\/b> that uses its extensive expertise in developing <b>innovative drugs for metabolic diseases<\/b>, with a focus on <b>type 2 diabetes<\/b> and <b>non-alcoholic steatohepatitis (NASH)<\/b>. In its mid-to-late-stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. <b>Imeglimin<\/b>, Poxel\u2019s first-in-class lead product, targets mitochondrial dysfunction. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. A Japanese new drug application (J-NDA) is under review by the Pharmaceuticals and Medical Devices Agency (PMDA) to request approval for the manufacturing and marketing of Imeglimin for the treatment of type 2 diabetes. After successfully completing a Phase 2a proof-of-concept trial for the treatment of NASH, which met its primary endpoint and study objectives, for<b> PXL770<\/b>, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, Poxel plans to initiate a Phase 2b program in the second half of 2021. PXL770 could also have the potential to treat additional metabolic diseases. <b>PXL065<\/b> (deuterium-stabilized R-pioglitazone), a MPC inhibitor, is in a streamlined Phase 2 trial for the treatment of NASH. Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxelpharma.com&amp;esheet=52362077&amp;newsitemid=20210114005819&amp;lan=en-US&amp;anchor=www.poxelpharma.com&amp;index=2&amp;md5=8257c1d1a6da80f9195b1542cbc1237c\">www.poxelpharma.com<\/a>.\n<\/p>\n<p>\nIn the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company is regularly reviewing the impact of the outbreak on its business.\n<\/p>\n<p>\nAs of the date of this press release, and based on publicly available information, the Company has not identified the occurrence of any material negative effect on its business due to the COVID-19 pandemic that remains unresolved. However, the Company anticipates that the COVID-19 pandemic could have further material negative impact on its business operations. The worldwide impact of COVID-19 may notably affect the Company\u2019s internal organization and efficiency, particularly in countries where it operates and where confinement measures are implemented by the authorities. In addition, COVID-19 may impact market conditions and the Company\u2019s ability to seek additional funding or enter into partnerships. Particularly, delays in the supply of drug substance or drug products, in the initiation or the timing of results of preclinical and\/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could potentially have an impact on the Company\u2019s development programs and partnered programs. The Company will continue to actively monitor the situation.\n<\/p>\n<p>\nAll statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company\u2019s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould\u201d and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company\u2019s control that could cause the Company\u2019s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.\n<\/p>\n<p>\n________________<br \/>\n<br \/><sup>1<\/sup> Year noted is Fiscal Year from April 2021 to March 2022, which is Sumitomo Dainippon Pharma\u2019s Fiscal Year.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210114005819r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210114005819\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210114005819\/en\/<\/a><\/span><\/p>\n<p><b>Poxel SA<br \/>\n<br \/><\/b>Aur\u00e9lie Bozza<br \/>\n<br \/>Investor Relations &amp; Communication Director<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:aurelie.bozza@poxelpharma.com\">aurelie.bozza@poxelpharma.com<br \/>\n<\/a><br \/>+33 6 99 81 08 36\n<\/p>\n<p><b>Investor relations \/ Media &#8211; EU\/US<br \/>\n<\/b><br \/>Trophic Communications<br \/>\n<br \/>Stephanie May or Valeria Fisher<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:may@trophic.eu\">may@trophic.eu<\/a> or <a rel=\"nofollow\" href=\"mailto:fisher@trophic.eu\">fisher@trophic.eu<br \/>\n<\/a><br \/>+49 171 185 56 82 or +49 175 804 1816\n<\/p>\n<p><b>Investor relations \/ Media &#8211; France<br \/>\n<\/b><br \/>NewCap<br \/>\n<br \/>Emmanuel Huynh or Arthur Rouill\u00e9<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:poxel@newcap.eu\">poxel@newcap.eu<br \/>\n<\/a><br \/>+33 1 44 71 94 94\n<\/p>\n<p><b>KEYWORDS:<\/b> New York Massachusetts United States France Japan North America Asia Pacific Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research FDA Diabetes Clinical Trials Other Health Biotechnology Pharmaceutical Health Science Other Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210114005819\/en\/729413\/3\/Logo_Without_Background.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Poxel Regains Imeglimin Rights From Metavant LYON, France&#8211;(BUSINESS WIRE)&#8211;POXEL SA (Euronext: POXEL &#8211; FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that, as part of the previously communicated decision by Metavant not to advance Imeglimin into a Phase 3 program for strategic reasons, its partnership agreement with Metavant will be terminated, effective January 31, 2021. Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program. Metavant is not entitled to any payment from Poxel as part of the return of the program. \u201cWe remain convinced of Imeglimin\u2019s value as &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Poxel Regains Imeglimin Rights From Metavant&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-415188","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Poxel Regains Imeglimin Rights From Metavant - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Poxel Regains Imeglimin Rights From Metavant - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Poxel Regains Imeglimin Rights From Metavant LYON, France&#8211;(BUSINESS WIRE)&#8211;POXEL SA (Euronext: POXEL &#8211; FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that, as part of the previously communicated decision by Metavant not to advance Imeglimin into a Phase 3 program for strategic reasons, its partnership agreement with Metavant will be terminated, effective January 31, 2021. Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program. Metavant is not entitled to any payment from Poxel as part of the return of the program. \u201cWe remain convinced of Imeglimin\u2019s value as &hellip; Continue reading &quot;Poxel Regains Imeglimin Rights From Metavant&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-14T16:48:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210114005819r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-regains-imeglimin-rights-from-metavant\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-regains-imeglimin-rights-from-metavant\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Poxel Regains Imeglimin Rights From Metavant\",\"datePublished\":\"2021-01-14T16:48:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-regains-imeglimin-rights-from-metavant\\\/\"},\"wordCount\":895,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-regains-imeglimin-rights-from-metavant\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210114005819r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-regains-imeglimin-rights-from-metavant\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-regains-imeglimin-rights-from-metavant\\\/\",\"name\":\"Poxel Regains Imeglimin Rights From Metavant - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-regains-imeglimin-rights-from-metavant\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-regains-imeglimin-rights-from-metavant\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210114005819r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-01-14T16:48:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-regains-imeglimin-rights-from-metavant\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-regains-imeglimin-rights-from-metavant\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-regains-imeglimin-rights-from-metavant\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210114005819r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210114005819r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/poxel-regains-imeglimin-rights-from-metavant\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Poxel Regains Imeglimin Rights From Metavant\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Poxel Regains Imeglimin Rights From Metavant - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/","og_locale":"en_US","og_type":"article","og_title":"Poxel Regains Imeglimin Rights From Metavant - Market Newsdesk","og_description":"Poxel Regains Imeglimin Rights From Metavant LYON, France&#8211;(BUSINESS WIRE)&#8211;POXEL SA (Euronext: POXEL &#8211; FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that, as part of the previously communicated decision by Metavant not to advance Imeglimin into a Phase 3 program for strategic reasons, its partnership agreement with Metavant will be terminated, effective January 31, 2021. Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program. Metavant is not entitled to any payment from Poxel as part of the return of the program. \u201cWe remain convinced of Imeglimin\u2019s value as &hellip; Continue reading \"Poxel Regains Imeglimin Rights From Metavant\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-14T16:48:32+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210114005819r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Poxel Regains Imeglimin Rights From Metavant","datePublished":"2021-01-14T16:48:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/"},"wordCount":895,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210114005819r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/","name":"Poxel Regains Imeglimin Rights From Metavant - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210114005819r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-01-14T16:48:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210114005819r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210114005819r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/poxel-regains-imeglimin-rights-from-metavant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Poxel Regains Imeglimin Rights From Metavant"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/415188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=415188"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/415188\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=415188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=415188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=415188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}